Three conditions had more than 1 gene or RNA therapy available: DMD (n = 4 drugs), SMA (n = 3 drugs), and polyneuropathy of hereditary transthyretin-mediated amyloidosis (n = 3 drugs). This evidence concerns the gene SMN1 and polyneuropathy.